Thanks to vaccines, widespread epidemics of illnesses such as smallpox, polio, diphtheria, measles, pertussis, and rubella may seem like a thing of the past. Vaccination is one of the safest and most effective prevention strategies of our time. Yet, vaccine-preventable diseases still pose significant threats to millions worldwide, especially children in developing countries.
Even when vaccines are available, they may not provide full protection against all forms of disease. This may be due to factors such as vaccine damage, inappropriate delivery, and the characteristics of the target population—which may differ from those of the populations where the vaccines were initially evaluated. What’s more, there are still many infectious diseases—that mainly affect poor countries—for which vaccines are not yet available.
That’s why AMP is collaborating with private- and public-sector partners to conduct field-based vaccine evaluations in developing countries. This information helps decision makers to reassess current strategies and to develop culturally relevant vaccination policies and schedules. And that means improved health for families and communities.
We also participate, to a smaller extent, in clinical trials to develop safe and effective vaccines. Our aim is to contribute to developing vaccines for diseases that hinder the livelihood and well-being of millions worldwide.